
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
The American Journal of Managed Care
over 29 years ago
Consideration in Pharmaceutical Conversion: Focus on Antihistaminesover 29 years ago
Issues in the Measurement of Satisfaction with Treatmentover 29 years ago
Abdominal Aortic Aneurysmover 29 years ago
Reducing Malpractice Risk Through More Effective Communication




